Aligos Therapeutics, Inc. has recently attracted attention from Parkman Healthcare Partners LLC, which has acquired a 5.2% stake in the company. This investment, disclosed in a Schedule 13G filing on November 13, 2026, indicates growing interest in Aligos and its potential within the biological products industry.
Aligos Therapeutics is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker symbol ALGS and has been actively involved in developing innovative therapies for various diseases.
The filing reveals that Parkman Healthcare Partners LLC, along with its affiliates, beneficially owns a total of 325,537 shares of Aligos's common stock. The filing states, "All of the securities reported in this Schedule 13G are directly owned by advisory clients of Parkman Healthcare Partners LLC." This suggests that the investment is part of a broader strategy to engage with Aligos's growth trajectory.
This acquisition may influence various stakeholders, including existing shareholders and potential investors, as it highlights confidence in Aligos's future prospects. Additionally, it positions Parkman Healthcare Partners as a notable player in the biotech investment landscape.
The filing does not specify what actions may follow this investment, leaving future developments uncertain.
Investment Structure and Control
The Schedule 13G filing indicates that the reported shares are owned by various entities associated with Parkman Healthcare Partners LLC, including Parkman Healthcare Partners Holdings LP, Parkman Healthcare Partners Holdings GP LLC, and Gregory Martinez. Each of these entities holds a beneficial ownership of 325,537 shares, representing a 5.2% stake in Aligos Therapeutics. This structure suggests a coordinated investment strategy among the entities, with Parkman Healthcare Partners LLC acting as the primary reporting entity.
Furthermore, the filing notes that none of the advisory clients of Parkman Healthcare Partners LLC may be deemed to beneficially own more than 5% of the common stock individually, indicating that the investment is diversified across multiple clients rather than concentrated in a single entity.
Regulatory Compliance
In compliance with SEC regulations, the filing includes a certification by Gregory Martinez, the Managing Member of Parkman Healthcare Partners LLC, affirming that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Aligos Therapeutics. This statement is crucial as it underscores the investment's intent, aligning with SEC guidelines for institutional investors.
Address and Contact Information
The business address for Aligos Therapeutics is listed as One Corporate Drive, 2nd Floor, South San Francisco, California 94080. Parkman Healthcare Partners LLC is located at 700 Canal Street, 2nd Floor, Stamford, Connecticut 06902. This information may be relevant for stakeholders seeking to engage with either entity directly.
The filing does not include any specific plans or intentions regarding the future involvement of Parkman Healthcare Partners with Aligos Therapeutics, nor does it elaborate on the strategic rationale behind this investment.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





